Through this alliance and procurement, the companies intend to leverage their medical, healthcare, and financial assets to improve the case accumulation rate and clinical trial implementation rate, and to strengthen the social implementation of the Japanese DCT ecosystem.

Background and Purpose of Capital and Business Alliance and Fund Procurement
Drug lag and drug loss caused by delays in new drug development and an increase in unapproved drugs have become major issues in building a stable medical system in Japan. In the clinical trial and clinical research area, there are several issues that need to be resolved in order to promote development and research more rapidly, such as "information on new drugs is not reaching the patients and medical institutions that need it" and "DXing of clinical trial operations is not progressing.
In order to solve these issues, the government has launched a series of measures to revitalize new drug development, such as deregulation, establishment of a clinical trial ecosystem*1, and promotion of DCT*2, and has initiated various initiatives to enable medical institutions conducting clinical trials to become involved in more clinical trials and clinical research earlier.
In DCTs, in particular, we are helping to develop the DX environment necessary to make clinical trials a more accessible medical option through e-recruitment, which recruits patients to participate in clinical trials online; e-consent, which uses electronic consent tools; online medical care, which allows patients to receive clinical trial care at home or at their family doctor; medical support through home nursing at the patient's home; and easing the delivery of investigational drugs to patients' homes, pharmacies, and family doctors. The DX environment is being improved to make clinical trials a more accessible medical option through the easing of delivery of investigational drugs to patients' homes, pharmacies, and family doctors.
In this environment, Buzzreach has developed the clinical trial and clinical research support platform "StudyWorks," the clinical trial information disclosure and management function "smt," case collection support for DCT-type subject recruitment using partner sites*3 , and the patient-specific social networking service "Miraiku" to realize centralized management of clinical trial operations on a platform targeting university hospitals, cancer centers, major group hospitals, etc. StudyWorks", a clinical trial information disclosure and management function "smt", case collection support for DCT-type subject recruitment using partner sites, and "Miraiku", a patient-specific SNS service.
Through the capital alliance and fund procurement with each company, we will not only step forward to solve new issues in the field of clinical trials and clinical research, but also to provide new value to medical institutions and patients who use the services of each company.
1 A system led by the Ministry of Health, Labour and Welfare (MHLW) that allows pharmaceutical companies, medical institutions, regulatory authorities, and patients as subjects to cooperate in efficiently conducting clinical trials.
2 Decentralized Clinical Trials. In the past, clinical trial-related tasks such as patient recruitment, in-hospital treatment, and medication administration were all required to be conducted at the medical institution conducting the clinical trial. Methods that allow patients to participate in clinical trials outside of medical institutions, such as at their family doctors or homes
3 Clinical trial cooperating medical institution for DCT
Buzzreach's future role
Buzzreach will focus on the following through this alliance
Standardization and automation of DX for clinical trial operations based on Study Works
Strengthening the ability to accumulate cases at investigational sites by expanding the network of partner sites
The DCT is a social implementation of Japanese-style DCT that combines the assets of various companies.
Establishment of investigational drug delivery and follow-up system including pharmacy and home care area
Specific contributions to the government's "Clinical Trials Ecosystem Initiative
Representative Comment (Takateru Inokawa, CEO, Buzzreach, Inc.)

The capital alliance and fundraising are the result of collaboration between MEDRAY, a leader in medical DX, M3, a leading medical information service company with approximately 90% of Japanese physicians registered, and M3 Group companies, and DG Resona, which has financial and payment infrastructure, partners with different strengths, The alliance will accelerate the social implementation of the Japanese version of DCT by strengthening the ability to accumulate cases at medical institutions conducting clinical trials through the promotion of partner site-based patient recruitment and by utilizing the assets of each partner company.
The Japanese clinical trial DX market is expected to expand rapidly in the future, backed by policy support and the digitization of clinical trial sites. As a "leading platform for social implementation of Japanese-style DCT" in this growing field, we will promote standardization of clinical trial infrastructure across industry, government, and academia through this alliance.
We will continue to collaborate with a wide variety of partners to create a new clinical trial infrastructure that organically links patients, medical institutions, and pharmaceutical companies, based on our philosophy of "providing new options to as many patients as possible through the power of technology.
Contribution to University Hospitals, etc. through this alliance
Many university hospitals, which play a central role in Japan's clinical trial environment, have been forced to operate at a severe loss due to soaring prices and labor costs, cuts in operating subsidies, etc. It is reported that 86% of hospitals will be in the red in FY2023, making stable hospital management difficult based on medical revenue alone. The situation is such that it is difficult to run a hospital stably on medical revenue alone.
As a part of efforts to overcome this situation, we will contribute to the development of university hospitals that conduct many clinical trials, the acceleration of clinical trials, and the implementation of medical innovation by developing a clinical trial infrastructure that will lead to increased efficiency in clinical trial operations and support for improved case accumulation through this alliance.

Buzzreach Corporation|Overview
| name of company | Buzzreach Inc. |
| Establishment | Jun 2017 |
| Location | Kowa Shirokanedai Building, 19-1, Shirokanedai 3-chome, Minato-ku, Tokyo |
| representative | Representative Director and CEO |
| Business Overview | Planning, development and operation of clinical trials and clinical research support platform Main services: Provision of clinical trial and clinical research support SaaS, DCT support business, development and operation of patient recruitment platform utilizing partner sites, patient SNS business, etc. |
| uniform resouce locator | https://www.buzzreach.co.jp |
Medley Corporation|Outline
| name of company | Medley Corporation |
| Location | Roppongi Hills Mori Tower 13F, 6-10-1 Roppongi, Minato-ku, Tokyo |
| representative | Kohei Takiguchi, President and Representative Director |
| Business Overview | Medical platform business (CLINICS, MALL, DENTIS, MEDIXS, MINET, etc.), Human resources platform business (JobMedley, JobMedley Academy, etc.) |
| uniform resouce locator | https://www.medley.jp |
M3 Corporation|Overview
| name of company | M3 Corporation |
| Location | Akasaka Intercity, 1-11-44 Akasaka, Minato-ku, Tokyo |
| representative | Representative Director Itaru Tanimura |
| Business Overview | Providing medical-related services via the Internet |
| uniform resouce locator | https://corporate.m3.com |
DG Resona Ventures No.1 Investment Limited Partnership|Outline
| name of company | DG Resona Ventures No.1 Investment Limited Partnership |
| Location | 15-1 Udagawa-cho, Shibuya-ku, Tokyo |
| Business Overview | CVC fund established to jointly promote open innovation and startup investment with the aim of creating business collaboration and synergies between Digital Garage (DG) and the Resona Group |
| uniform resouce locator | https://dg-resona-v.com/ |









